Stool Alpha-1 Antitrypsin Diagnostics Market: Inflammatory Bowel Disease Segment to be Highly Attractive

Alpha-1 antitrypsin (AAT) is a protein produced in the liver that circulates through blood. The alpha-1 antitrypsin protein primarily protects the body’s own tissues and cells from being damaged by activated immune response to foreign infection, autoimmune disorder, and other foreign particles.

Stool Alpha-1 Antitrypsin Diagnostics: Introduction

  • Alpha-1 antitrypsin (AAT) is a protein produced in the liver that circulates through blood. The alpha-1 antitrypsin protein primarily protects the body’s own tissues and cells from being damaged by activated immune response to foreign infection, autoimmune disorder, and other foreign particles.
  • AAT protein is crucial in maintaining regulatory and anti-inflammatory response during the immune response to foreign particles. Thus, it protects healthy cells and tissues. This protective characteristic of AAT is being considered a key biomarker for the diagnosis of various inflammatory, gastrointestinal, and immunological disorders.

Read Report Overview - https://www.transparencymarketresearch.com/stool-alpha1-antitrypsin-diagnostics-market.html

  • Various gastrointestinal and inflammatory disorders show abnormal levels of AAT in stool sample. AAT is commonly present in high quantities in inflammatory bowel diseases, celiac diseases, necrotic enterocolitis, colon cancer, Whipple disease, colon polyps, and systemic lupus erythematosus.
  • The stool AAT diagnostic test is non-invasive. It is commonly performed using ELISA technology. It is used in conjunction with diagnostic test as a complementary test.

Stool Alpha-1 Antitrypsin Diagnostics Market: Key Drivers

  • High prevalence and rise in incidence rate of gastrointestinal disorders such as inflammatory bowel disease and celiac disease across the globe is one of the key factors driving the stool alpha-1 antitrypsin diagnostics market
  • According to a research article published in the Lancet Journal in 2017, there were more than 6.7 million people afflicted with the inflammatory bowel disease across the globe in the year

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78385

  • Around 2.5 million to 3 million people in Europe are affected by the inflammatory bowel disease per year. Highest incidence and prevalence of the inflammatory bowel disease is observed in Scandinavia and the U.K. Incidence of Crohn’s disease in Europe ranges from 0.5 to 10.6 cases per 100,000 people per year, while that of ulcerative colitis ranges from 0.9 to 24.3 per 100,000 per year.
  • Low cost of the test, ease of conducting the test, non-invasive nature of the test, and high clinical importance of stool alpha-1 antitrypsin are estimated to boost the market during the forecast period

Inflammatory Bowel Disease Segment to be Highly Attractive

  • In terms of indication, the global market can be segmented into inflammatory bowel disease, necrotic enterocolitis, celiac disease, systemic lupus erythematosus, and others. The inflammatory bowel disease segment is estimated to dominate the market during the forecast period.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=78385

Diagnostic laboratories to be Highly Attractive Segment

  • Based on end-user, the global stool alpha-1 antitrypsin diagnostics market can be classified into hospitals, diagnostic laboratories, and academic and research institutes. The diagnostic laboratories segment is projected to dominate the global market during the forecast period.
  • Presence of large numbers of diagnostic laboratories, easy availability and accessibility of test at these centers, and low cost are factors that are likely to drive the diagnostic laboratories segment in the near future

Asia Pacific Stool Alpha-1 Antitrypsin Diagnostics Market to Expand Rapidly

  • In terms of region, the global stool alpha-1 antitrypsin diagnostics market can be split into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America is likely to dominate the global market during the forecast period. High prevalence of inflammatory bowel disease and necrotic enterocolitis and growth in aging population are factors expected to boost the market in the region during the forecast period.
  • The stool alpha-1 antitrypsin diagnostics market in Asia Pacific is anticipated to expand at a fast-paced CAGR during the forecast period. Rapid growth of the market in the region can be ascribed to rise in incidence rate of inflammatory bowel disease and necrotic enterocolitis in densely populated countries such as India and China, and improvement of health care infrastructure in the region.
  • High growth rate of the health care industry, easy access to health care facilities, and increase in investments in health care by leading players in Asia Pacific are expected to fuel the market in the region in the near future

Pre Book Stool Alpha-1 Antitrypsin Diagnostics Market Report at - https://www.transparencymarketresearch.com/checkout.php?rep_id=78385&ltype=S

Key Players Operating in Global Stool Alpha-1 Antitrypsin Diagnostics Market

The global stool alpha-1 antitrypsin diagnostics market is fragmented, with large number of global players holding majority share. Prominent players operating in the global stool alpha-1 antitrypsin market include:

  • ORGENTEC Diagnostika GmbH
  • R-Biopharm AG
  • Tecan Trading AG (IBL International GmbH)
  • Immundiagnostik AG
  • BioVendor Group
  • LifeSpan BioSciences, Inc.
  • RayBiotech, Inc.
  • Eagle Bioscience, Inc.

More Trending Reports by Transparency Market Research:

Robotic Rehabilitation and Assistive Technologies Market: Technological innovations in the robotic rehabilitation and assistive technologies landscape are offering people a second look at overcoming disability challenges. Modern technology in robotics is not only making the lives of disabled and elderly patients easier, but also improving their body functionalities.

Refurbished Dental Equipment & Maintenance Market: For people starting a new dental practice, buying necessary equipment can be struggling and complex. They need to identify the right tools and make sure it fits in their budget. Equipment such as digital image equipment, supplies, and structural upfit can cost new dental practices over US$ 500,000. As most new dental practices have a limited budget to purchase dental equipment, considering alternatives can be a suitable solution.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/